We are a privately-held biotechnology startup based in Stamford, Connecticut.
OncoSynergy technologies were developed at several world-class institutions including by our founders at UCSF and by 2013 Nobel Prize in Chemistry awardee, Martin Karplus of Harvard University.
Our therapies are drug platforms featuring “Targeted Synergy”—single drug inhibition of multiple cancer growth and resistance pathways for optimal safety and effectiveness.
Our lead drug, OS2966, is under development for the treatment of glioblastoma.
Location: United States, Connecticut, Stamford
Employees: 1-10
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 04.05.2018 | OncoSynergy Raises Series A Funding Round | OncoSynergy, a South San Francisco, CA-based oncology therapeutics spinout from UCSF, closed a Serie... | finsmes.co... |